Skip to main content

Table 3 Baseline characteristics of patients stratified according to HbA1c at baseline

From: High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

Characteristic HbA1c <6.5% (n = 86) HbA1c ≥6.5% (n = 40) p Value
Males 65 (75.58%) 31 (77.50%) 1.0000a
Age (years) 62.5 ± 7.9 62.8 ± 7.4 0.8390b
Body weight (kg) 64.81 ± 10.63 67.65 ± 14.51 0.2176b
BMI (kg/m2) 24.68 ± 2.71 25.67 ± 4.23 0.1186b
Lesion length 11.095 ± 3.398 10.213 ± 3.548 0.1835b
Lesion location
Proximal 15 (17.44%) 18 (45.00%)  
Distal 33 (38.37%) 7 (17.50%)  
Other 38 (44.19%) 15 (37.50%)  
Target vessel
RCA 35 (40.70%) 16 (40.00%)  
LAD 25 (29.07%) 13 (32.50%)  
LCX 26 (30.23%) 10 (25.00%)  
LMT 0 (0.00%) 1 (2.50%)  
LLT before enrolment 62 (72.09%) 30 (75.00%) 0.8308a
Hypertension 65 (75.58%) 31 (77.50%) 1.0000a
Smoking 22 (25.58%) 14 (35.00%) 0.2954a
Diabetes mellitus 9 (10.47%) 38 (95.00%) <0.0001a
Family history of CAD 19 (22.09%) 7 (17.50%) 0.6411a
Concomitant therapy
Ca channel blocker 46 (53.49%) 26 (65.00%) 0.2507a
Nitrate 57 (66.28%) 24 (60.00%) 0.5512a
ACE inhibitor 16 (18.60%) 11 (27.50%) 0.3507a
ARB 39 (45.35%) 17 (42.50%) 0.8481a
β-blocker 22 (25.58%) 7 (17.50%) 0.3697a
Thiazolidinedione 0 (0.00%) 9 (22.50%) <0.0001a
Sulfonylurea 3 (3.49%) 18 (45.00%) <0.0001a
α-glucosidase inhibitor 4 (4.65%) 17 (42.50%) <0.0001a
Insulin 1 (1.16%) 10 (25.00%) <0.0001a
Ticlopidine 83 (96.51%) 38 (95.00%) 0.6522a
Clopidogrel 5 (5.81%) 2 (5.00%) 1.0000a
Aspirin 86 (100.00%) 40 (100.00%) 1.0000a
  1. Data are means ± SD or n (%).
  2. aχ2 or Fisher’s exact test; btwo-sample t-tests.
  3. RCA, right coronary artery; LAD, left anterior descending; LCX, left circumflex; LMT, left main trunk; LLT, lipid-lowering therapy; CAD, coronary heart disease; HDL-C, HDL-cholesterol; IVUS, intravascular ultrasound; ARB: angiotensin receptor blocker.